Eisai ups commitment to oncology with new US R&D subsidiary
This article was originally published in Scrip
Executive Summary
Eisai is to pump at least $200 million over 10 years into exploratory research at a new US subsidiary set up to strengthen its activities in oncology R&D.
You may also be interested in...
Eisai Parades Pipeline Before Investors During First US R&D Day
Management highlighted Eisai’s neurology and oncology assets during a Scientific Day in New York, the first formal R&D briefing the Japanese pharma’s US subsidiary has held in more than 20 years operating in the country.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.